Three-dimensional bone tissue substitute based on a human mesenchymal stem cell culture on a nanofiber carrier and inorganic matrix

Martin Krbec1, Lukáš Plíštil2, Eva Matoušková2, Václav Mandys3, Jakub Ježek1, Markéta Sedlinská4, Valér Džupa1

University Hospital Královské Vinohrady, 1Department of Orthopaedics and Traumatology, 2Centre for Applied Bioimplantology, 3Institute of Pathology, Prague, Czech Republic 4University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Veterinary Medicine, Equine Clinic, Department of Reproduction, Brno, Czech Republic

Received December 4, 2015
Accepted February 10, 2016

Abstract

The aim was to construct a composite structure for bone tissue substitute on the basis of a degradable composite of an organic nanofiber carrier and an inorganic matrix in 3D, and to achieve subsequent colonisation by differentiated human mesenchymal stem cells (hMSC) towards osteocytes. We developed an active bone tissue substitute using nanofiber technology for a polycaprolactone (PCL) scaffold with the addition of hydroxyapatite and the colonisation of both components with hMSC with the ability of differentiation towards osteocytes. The constructed composition included the components necessary for bone healing (inorganic and cellular) and it also forms a spatially-oriented 3D structure. We used polycaprolactone Mw 70,000 with electrostatic spinning for the formation of nanofibers using a modified NanospiderTM method. For the inorganic component we used orthophosphate-calcium silicate with a crystal size of 1-2 mm which the nanofiber membrane was coated with. Both components were connected together with a tissue adhesive based of fibrin glue. Cultivated hMSC cells at a concentration of 1.2 × 1011/cm² were multiplied in vitro and then cultivated in the expansion medium. HMSC overgrew both the PCL membrane and the Si-CaP crystals. After colonisation with cultivated cells, this composite 3D structure can serve as a three-dimensional bone tissue replacement.

Bone substitution, polycaprolacton, nanotissue, biodegradable scaffold, hydroxyapatite, hMSC

The aim of the work was to construct a 3D composite structure for a bone tissue substitute based on a degradable composite of organic nanofiber carrier and inorganic matrix and to achieve subsequent colonisation towards osteocytes by differentiated human mesenchymal stem cells (hMSC). This device will be useful as a bone tissue substitute for needs in the field of orthopaedics and traumatology. It can be used, in particular, for treatment of bone defects, namely after injuries accompanied by bone loss, after resection surgeries in orthopaedics e.g. after removal of malignant tumours and for the treatment of unhealed bone fractures and non-unions. It can also be used to potentiate the healing of fractures.

The subject of bone healing and substitution of bone tissue is still being explored (Venugopal et al. 2008; 2010). The current commonly used method is the use of bone cement based on polymethyl methacrylate or metal substitutes on the basis of titanium and its alloys, recently on the basis of porous tantalum (trabecular metal). The disadvantage of these methods is the fact that it is a foreign material which is not structurally integrated into the bone. It has different elasticity and strength; it increases the risk of complications such as infection and the risk of mechanical failure.

Another possibility is the use of autologous or allogeneic bone grafts. These bone transplants are for many reasons considered obsolete because they are limited by the volume of useable material (autologous) and associated with defined risks of complications (allogeneic), such as the risk of infectious disease transmission from donor to recipient (similar to e.g. blood transfusion) or slow healing.
Synthetic or inorganic bone tissue substitutes are used in practice but their efficiency is questionable based on the available data in the literature and they are suitable only for limited indications.

Inorganic bone tissue substitutes on the basis of hydroxyapatite, which is the main component of the mineral portion of the bone matrix, have recently been used in practice mainly for their mechanical strength. Substitutes based on Ca sulphate, Ca phosphate and silicates are being tested. The inorganic component adds strength and, after implantation, it is in the optimal case colonised and slowly intergrown by the recipient’s own bone cells, so that in time bone remodelling occurs. A new approach in the development of active bone tissue substitute is the use of nanofiber technology to create the carrier (Parizek et al. 2012; Rim et al. 2013; Shalumon et al. 2013; Amler et al. 2014) in combination with the addition of hydroxyapatite and using the possibility of colonisation of these components with suitable cells capable of differentiating towards osteocytes (Martins et al. 2010; Ba Linh et al. 2013; Gandhimathi et al. 2013; Lyu et al. 2013; Gahawar et al. 2014; Novotna et al. 2014).

The initial intention was based on the requirement that the constructed composition should include all the components necessary for bone healing (inorganic and cellular) and that it should also form a standard spatially-oriented 3D structure, mechanically durable and processable for application to bone defects. For this purpose, a nanofiber biodegradable carrier and fibrin glue were used in addition to components for bone healing.

### Materials and Methods

**Chemicals and feedstock**

Polycaprolactone (PCL), Mw 70,000 (Scientific Polymer Products, USA); formic acid, acetic acid, standard solutions May-Grünwald, Giemsa-Romanowski (Penta, Czech Republic); Actifuse™ microgranules (porous crystals of 1–2 mm in size, orthophosphate and calcium silicate, silicon content 0.8%, ApaTech, UK); Artiss (human fibrin sealant, Baxter, USA); PBS, alizarin red S (P-Lab, Czech Republic); dexamethasone, ascorbyl-2-phosphate, glycerol-2-phosphate, Triton X-100, MgCl₂ (Sigma-Aldrich, USA); gene expression assays RUNX2, BMP2, IBSP, GAPDH, AND BGLAP (Life Technologies, USA).

**Preparation of the organic carrier**

As the material for nanofiber formation, we used the synthetic polyester polycaprolactone known for its biodegradability within several months (Salgado et al. 2012) and biocompatibility to hMSC (Valonen et al. 2010; Ko et al. 2015). The prepared nanofiber membrane from PCL had a basis weight of 36 g/m², thickness of 200 µm and a fibre diameter of 110 ± 40 nm (Plate IX, Fig 1, and Fig 2).

The nanofiber membrane was prepared with electrostatic spinning using a modified Nanospider™ method. The method is based on simultaneous formation of charged polymer solution streams on the surface of a thin wire electrode (Forward et al. 2012). The polymer solution was prepared as follows: 18.0 g of polycaprolactone (PCL) were added to a stirred mixture of formic acid (20.5 g) and acetic acid (61.5 g). The mixture was stirred at 50 °C until complete polymer dissolution occurred (about 3 h). The polymer solution was then cooled to room temperature and spun at a voltage of 80 kV; electrode distance of 150 mm; relative air humidity of 33% at 22 °C. As the collecting base material, we used an antistatic polypropylene spunbond (Atex, IT, 20-30 g/m²) which was moving at 14 mm/min. The nanofiber membrane was then washed for 7 days with tissue water to remove residual solvents, then sterilised for 30 min under UV-C radiation and subsequently seated in sterile round handle Cellcrown6 (5 cm²; Scaffdex, FIN). The nanofiber membrane was designated hereinafter as the component α of the composite.

**Preparation of the PCL-Si-CaP composite**

As the inorganic component of the composite (designated β), we used a commercially available microcrystalline product Actifuse (silicon content 0.8 %) with a crystal size of 1–2 mm which the surface of PCL nanofiber membrane was coated with. A sterile fibrin glue Artiss (200 µl) was uniformly added to the membrane surface drop by drop and then orthophosphate-calcium silicate (Si-CaP Actifuse, 200 mg) crystals were regularly placed there. The fibrin was left to solidify for 1 h.

Thus we created a nanofiber-Si-CaP composite in a 3D form from the components α and β.
Both components were connected together with a tissue adhesive on the basis of fibrin (Artiss). The overall appearance of the composite is shown in Fig. 3 a,b (Plate IX).

Preparation of cell suspension and cultivation

Human mesenchymal stem cell isolation

Human MSC were obtained from adipose tissue samples removed during surgeries. The tissue sample (1 cm$^3$) was cut and immersed in 0.1% collagenase I (Roche) (dissolved in H-MEM medium with 10% serum) for 4 h at 37 °C. The tissue was then stretched several times with a pipette until it disintegrated. The cell suspension was centrifuged (600 × g, 10 min), the supernatant removed and the cell pellet re-suspended and seeded onto 1–2 culture flasks with the surface of 25 cm$^2$.

Human mesenchymal stem cell cultivation

Human MSC at a concentration of 1.2 × 10$^4$ cells/cm$^2$ were seeded onto composites fixed in Cellcrown6 and cultivated in 6-well plates (Nunc, DEN) in 5 ml of expansion or differentiation medium at 37 °C, 3.5% CO$_2$ for 7, 14, and 21 days. The same conditions were used also for the control samples cultivated on the bottom of culture dishes. The medium was changed every 3 days.

Composition of media: expansion – H-MEM enriched with non-essential amino acids, 0.12 g/l of sodium pyruvate, 1 g/l NaHCO$_3$, 10% of bovine serum, 2% of foetal bovine serum, 2.5 ng/ml EGF, 200 µg/ml penicillin, 100 µg/ml streptomycin; differentiation medium – expansion medium enriched with 100 nM dexamethasone, 50 µg/ml ascorbyl-2-phosphate, 10 mM glycerol-2-phosphate.

To visualise the cells, we used the standard May-Grünwald and Giemsa-Romanowski staining. Formation of hydroxyapatite in control samples was detected by alizarin red staining (2% solution, pH ~ 4.5, 15 min, 25 °C) after formalin fixation (4% solution in PBS, 15 min).

The quality of hMSC was analysed by their activity against antigen of the surface proteins CD34, CD73, CD90, CD105; and by their ability to differentiate into osteoblasts. Human MSC grown on composites were cultivated in vitro in a differentiation medium for osteoblasts for 21 days. The differentiation was proved microscopically, by an increased production of alkaline phosphatase (ALP) and the presence of mRNA coding ossification proteins (osteocalcin, osteopontin, runt-related transcription factor 2).

The cellular component of the future composite was designated as component γ.

Microscopy

Morphology of the nanofiber membrane was analysed using a scanning electron microscope FEI Quanta 200 (with a secondary electron detector Everhart-Thornley) (Plate IX, Fig. 1); samples were covered with a thin layer of gold and observed under high vacuum. The fibre diameter was determined using NIS Elements 4.0 (Laboratory Imaging, Czech Republic). Three samples were taken from the nanofiber material and at least 50 individual fibres were measured in them.

The composite material after colonisation of hMSC was then viewed using an Olympus IX71 optical microscope (Plate X, Fig. 4a,b).

Fig. 2. A frequency diagram showing the distribution of fibre diameters
Results

The solution subject is a device for use as a 3D composite bone tissue substitute consisting of three components (Table 1).

Table 1. The three components of the 3D composite bone tissue substitute.

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>α</td>
<td>Nanofiber membrane on the basis of biocompatible polycaprolactone</td>
</tr>
<tr>
<td>β</td>
<td>Porous inorganic material – orthophosphate-calcium silicate crystals</td>
</tr>
<tr>
<td>γ</td>
<td>Cultivated human mesenchymal stem cells differentiated into osteocytes in the form of suspension</td>
</tr>
</tbody>
</table>

Component α was a nanofiber carrier (membrane) which was prepared by electrostatic spinning of polymeric solution of biodegradable and hMSC biocompatible polycaprolactone (PCL) using a modified Nanospider™ method. Component β was composed of a commercially available inorganic porous matrix. It comprised orthophosphate-calcium silicate (Si-CaP, Actifuse, 200 mg) crystals. The crystals were fixed on the surface of the nanofibre membrane with a fibrin glue. Component γ consisted of cultivated hMSC at a concentration of $1.2 \times 10^4$ cells/cm$^2$. The cells derived from adipose tissue were first multiplied in vitro and then cultivated in the presence of the composite in the expansion medium.

In the first stage, toxicity of the PCL-Si-CaP composite for hMSC was observed. The cells derived from adipose tissue were first multiplied in vitro and then cultivated in the presence of the composite in the expansion medium. After seven days of cultivation, the composite was stained, its components disintegrated and cells on individual components of the composite were visualised (Plate XI, Figs 5 and 6). It is evident from the microscopic pictures that hMSC overgrew both the PCL membrane and Si-CaP crystals. It was also found that hMSC were not able to penetrate through the nanofiber membrane. The hMSC differentiation into osteocytes was demonstrated microscopically by an increased production of alkaline phosphatase (ALP) (Fig. 7) and the presence of

![Fig. 7. The results of the spectrophotometric analysis of ALP present in the hMSC samples](image-url)
mRNA coding the ossification proteins. Figure 7 shows that the concentration of ALP increased in the osteo-differentiation medium which is considered one of the proofs of differentiation of MSC into osteoblasts.

After colonisation with cultivated cells the composite structure prepared in this way can serve as a three-dimensional bone tissue replacement (Plate XI, Figs 5 and 6).

**Discussion**

Essential requirement for the creation of a bone tissue substitute is the choice of a suitable material with good structural and mechanical properties that is not toxic to cell culture, does not prevent cell proliferation, differentiation and formation of new bone tissue and, in particular, is fully biodegradable (Rodrigues et al. 2012; Araújo et al. 2015). We chose a combination of two materials: a nanofibre membrane prepared from a biodegradable and biocompatible polymer (Eap et al. 2012, 2015; Guo et al. 2013) and an inorganic substrate – orthophosphate-calcium silicate (Si-CaP). This selection was based on the following reasons: Si-CaP is the active ingredient of commercially available bone tissue replacements; its presence is shown to promote angiogenesis and osteogenesis; it is further resorbed to hydroxyapatite in bone tissue (Hing et al. 2007); and the nanofiber morphology is very similar to the structure of the extracellular matrix, thereby promoting cell proliferation (Franco et al. 2014). The biodegradable polymer gives the cells a temporary support when colonising the substitute and it decomposes after a certain time, leaving only the resorbed inorganic component with a layer of bone tissue cells in the bone tissue (Bhattacharyya et al. 2009).

Unlike some previous works (Venugopal et al. 2008; Prosecka et al. 2012), we created a nanofiber-Si-CaP composite in a 3D form.

One of the conditions for successful bone repair is the growth rate and a sufficient number and quality of hMSC in the anticipated place of healing (Muschler et al. 2001; Prosecka et al. 2011; De Santis et al. 2015). In bone defects, however, the activity of hMSC is lower and it is necessary to look for ways to stimulate this process in bone healing (Necas et al. 2010). One possibility is to enrich the place of healing with autologous hMSC or bone substitute with already cultured autologous hMSC (Crha et al. 2009) which is the method we chose, too.

The composite structure prepared in this way, with the carrier construction using nanotechnology for the processing of organic biodegradable materials in combination with an organic matrix containing mineral resources essential for osteogenesis, can after colonisation with cultivated cells serve as a three-dimensional bone tissue replacement with the potential for rapid reconstruction and remodelling. It can be mechanically processed into a multilayer structure (Plate IX, Fig. 3b) that can be used for filling bone defects or strengthening pseudoarthroses by the method of biological stimulation, replacing open spongioplasty to accelerate the healing of pseudoarthroses.

Although these promising features of the material were proved experimentally *in vitro*, it is necessary to investigate its use in bone defect healing in an animal model in upcoming *in vivo* experiments on miniature pigs. Only thereafter a study for *in vivo* testing in humans would be designed.

**Acknowledgement**

This work was supported by the Internal Grant Agency of Ministry of Health of the Czech Republic IGA NT 14438.

**References**

Venugopal JR, Low S, Choon AT, Kumar AB, Ramakrishna S 2008: Nanobioengineered electrospun composite nanofibers and osteoblasts for bone regeneration. Artif Organs 32: 388-397
Fig. 1. Scanning electron microscopy picture of PCL nanofiber layer (magnification × 20,000)

Fig. 3 a,b. Scheme of the PCL-Si-CaP-fibrin composite: 1 - nanofiber matrix, 2 - inorganic component fixed with fibrin glue. A top view, a side view (a), the possibility of layering (b)
Fig. 4 a,b. Images of vital hMSC stained with May-Grünwald, Giemsa-Romanowski cultivated for 7 days in the expansion medium a) on Si-CaP crystals (magnification × 4); b) on PCL nanofiber membrane (magnification × 10).
Fig. 5. PCL-Si-CaP-fibrin composite

Fig. 6. PCL-Si-CaP-fibrin composite after processing, before colonisation with hMSC